Biotech Company Accelerates AI Detection Breakthrough Globally

1. Mindbio Therapeutics Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
2. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
3.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
4. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) upsized its private placement to CA$1.5 million. 

On February 18, 2026, MindBio announced its non-brokered private placement offering up to CA$650,000, but that number has been expanded. As of March 19, 2026, the company has chosen to offer up to 2,500,000 units of the company at CA$0.60 per unit, totaling up to CA$1.5 million in potential investment.

Each unit sold will be comprised of one share of the company and one share of a purchase warrant, entitling the buyer to acquire an additional share at US$0.80 for up to three years. This offer is subject to change should the CSE closing price exceed CA$1.00 for ten consecutive trading days.

MindBio is also offering finders' fees for certain third-parties who bring in new investors.

The AI Health Metric Company   

MindBio Therapeutics Corp. is a Canadian biotech company intent on leveraging AI technology to analyze the human voice and detect impairment due to alcohol or illicit substances. Through the development of personal-use smartphone apps and mass-use corporate kiosks, MindBio is developing software that could help reduce accidents due to intoxication. The proprietary technology analyzes up to 140 vocal markers, focusing on parameters like spectral entropy, jitter and shimmer, and speech rate variability.

The company states its vision as developing, "A world where voice-based biomarkers are a standard component of healthcare—enabling continuous, passive health monitoring that catches problems early and improves outcomes for everyone, everywhere."

Currently, MindBio is developing inroads into the mining, aviation, construction, and law enforcement industries.

Edge Kiosk in Development

The company's personal-use app, Booze AI, is live and described as "the world's first voice-activated AI-powered blood alcohol test" and is deployed via smartphone. It provides private, instant results through prompting its user to complete basic speech and behavioral tasks via voice. The goal is to promote social responsibility, personal awareness, and harm prevention among individual users.

Now, however, MindBio has focused its attention on commercial applications and is currently building Edge-AI kiosks to implement non-invasive intoxication screenings at large mining sites.

In an interview with Streetwise Reports, MindBio CEO, Justin Hanka, gave insight into the difficulty mining operations face in shouldering the economic burden of screening employees: "In Chile, there are about 220,000 mining workers going on and off site every day. If you had to test 10% of them every day—that's 20,000 workers. If you were charged just US$1 for every test, that's US$20,000 a day, seven days a week . . . and that's just one part of the world, and two mining sites that I have access to."

Current screening techniques in zero-tolerance industries can be invasive, time consuming, costly, and make a worker appear targeted. MindBio aims to provide the benefits of screening without the pitfalls. "The core reason why a company wants to do this is that 25% of incidents are caused by alcohol and drug intoxication, directly or indirectly," Hanka said to Streetwise Reports.

When questioned about how the technology might interpret different languages, dialects, or speech patterns, Hanka said, "It's language agnostic. It's accent agnostic," noting that the markers tested change uniformly with intoxication, regardless of gender, dialect, or language. The application of this AI system allows for the potential to administer tox screenings in a non-discriminatory and scalable way.  

The company is currently working with mining corporations but is exploring other applications for its voice AI technology.

The Catalyst

According to the company's latest presentation, MindBio aims to deploy its Edge AI voice drug and alcohol detection kiosks in June of 2026, hoping to test at scale in zero-tolerance industries. The company is already partnering with mines in South America and is in talks with other industries. While enterprise and telehealth capacities are in development right now, future plans include disease prediction and health optimization.

Market Shows Need for Screening Technology

In a recent market presentation, MindBio said that detecting drug and alcohol intoxication at scale can prevent unnecessary harm by detecting physiological decline, citing the dangers of impaired driving and a 10-20x increase in suicide risk while heavily intoxicated. It also estimates that 40-50% of suicides involve alcohol, while the global alcohol harm cost sits at around US$1.6 trillion.

Many factors contribute to addiction and abuse risk, like parental monitoring, peer pressure, socioeconomic status, type of substance, stress, drug availability, and occupation, according to the American Addiction Centers. They classify the mining industry as "particularly conducive to substance abuse," due to job stress, physical demand, and injuries from prolonged work.

Biotech, in general, has also shown exponential growth recently. "The global biotechnology market size was estimated at US$1.55 trillion in 2023 and is projected to reach US$3.88 trillion by 2030, growing at a CAGR of 13.96% from 2024 to 2030," said Grandview Research. In September 2025, Market and Market Analysis considered the AI detector market as "undergoing rapid expansion, with estimates projecting a substantial market value surge from approximately US$0.58 billion in 2025 to US$2.06 billion in 2030."

According to the Experts

On February 3, 2026, The Canadian Mining Journal reported that, "Studies in Chile reveal that alcohol consumption among mining workers exceeds 75%, with over 40% classified as problem drinkers." The article presented the potential efficacy of MindBio's kiosks in accident prevention, saying, "A single preventable incident can cost a mining company hundreds of millions in lost production, union boycotts, and insurance and medical expenses."

Knowlton Thomas, for Techcouver, wrote on January 26, 2026, that ". . . Leveraging more than 50 million data points from drug and alcohol clinical trials and proprietary algorithms across over 100 acoustic parameters, MindBio is now commercializing its technology." 

Ownership & Share Structure¹

Management and Insiders own approximately 5.80% of MindBio Therapeutics shares, with retail investors holding the remaining 94.20%. The company's current market cap is CA$4.5 million, with a 52-week trading range of CA$0.50-CA$8.00.